Japan's Daiichi Sankyo mulls sale of OTC drugs unit, hires JPMorgan

Photo by pina messina on Unsplash

Japan’s Daiichi Sankyo Co is exploring the sale of its over-the-counter drugs (OTC) business and has hired JPMorgan to advise on the potential deal, several people with knowledge of the matter told Reuters.

Japan’s No.4 drugmaker by revenue has been focused on developing cancer treatments to offset a revenue drop following patent expirations of its mainstay high blood pressure drug.

Bring stories like this into your inbox every day.

Sign up for our newsletter - The Daily Brief
Subscribe to Newsletter